Myeloma and Plasma Cell Dyscrasias
October 2-5, 2020
Westin Copley Place
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts
Irene Ghobrial, Dana-Farber Cancer Institute, Boston, Massachusetts
Myeloma is one of the most commonly diagnosed blood cancers in the United States, with an estimated 32,270 new cases in 2020. Patient outcomes have improved over the last few years due to the development and FDA approval of novel therapeutics such as immunomodulatory agents (lenalidomide), immunotherapeutics (daratumumab), and proteasome inhibitors (bortezomib). New therapeutic options remain a priority to counter a lack of response to treatment and treatment resistance or relapse. This first AACR conference on myeloma and plasma cell dyscrasias will explore new advances in basic and translational cancer science in hopes of improving clinical outcomes.
For information on tabletop exhibits, please contact email@example.com. Space is limited.
Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available